Actively Recruiting
Study of CDX-1140 with Capecitabine, Oxaliplatin, and Keytruda in Adults with Advanced Biliary Tract Carcinoma
Led by National Cancer Institute (NCI) · Updated on 2026-10-30
60
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying advanced biliary tract carcinoma BTC, a cancer affecting the livers fluid-carrying tubes, which has limited treatment options and low survival rates. This trial aims to test the safety and effectiveness of a study drug called CDX-1140 combined with three other drugscapecitabine, oxaliplatin, and Keytrudain adults with BTC that has progressed after prior treatment and cannot be treated with surgery or liver transplant. Participants will receive treatment in 21-day cycles for up to six cycles. Oxaliplatin is given intravenously on day 1, capecitabine is taken orally twice daily for the first two weeks, and Keytruda and CDX-1140 are given intravenously on day 8 of each cycle. After six cycles, intravenous treatments continue only on day 1 of each cycle, and capecitabine is stopped. Imaging scans to monitor the disease will be done every nine weeks. Participants may continue the study treatment for up to two years, followed by three years of follow-up visits including imaging. During the study, participants will undergo physical exams, blood tests, heart function tests, imaging scans, and possibly biopsies to assess tumor status. Researchers will measure outcomes like safe dosing, progression-free survival at six months, and overall response rate. Safety and survival will also be monitored for up to five years. Imaging and other assessments may be done at different locations and results sent to the research team. Participation may last several years including treatment and follow-up.
CONDITIONS
Brief Title
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
Research Team
D
Donna Hrones, C.R.N.P.
T
Tim F Greten, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here